Boston Scientific (NYSE:BSX) Director Edward Ludwig Acquires 3,580 Shares of Stock

Boston Scientific Corporation (NYSE:BSX) Director Edward Ludwig purchased 3,580 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This represents a 16.44% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Boston Scientific Stock Performance

NYSE:BSX opened at $57.08 on Friday. The company has a 50-day moving average of $62.21 and a 200-day moving average of $80.40. The firm has a market cap of $84.84 billion, a price-to-earnings ratio of 23.88, a price-to-earnings-growth ratio of 1.04 and a beta of 0.62. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a twelve month low of $52.52 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts forecast that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Boston Scientific declared that its board has initiated a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Multiple Boston Scientific directors bought shares this week, including David C. Habiger, Edward J. Ludwig, and Cheryl Pegus. Heavy insider buying is often seen as a vote of confidence from management and can boost investor sentiment. Article Title
• Positive Sentiment: Boston Scientific reported positive pivotal trial results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter, with the FRACTURE trial meeting all primary safety and effectiveness endpoints. That strengthens the case for future regulatory approval and supports the company’s growth story. Article Title
• Neutral Sentiment: Baird kept an Outperform rating on BSX but trimmed its price target to $75 from $78, suggesting Wall Street still likes the name even as expectations are being adjusted. Article Title
• Negative Sentiment: Some recent commentary said Boston Scientific fell due to weak results, which may be weighing on sentiment and reminding investors that the stock has faced pressure despite longer-term growth prospects. Article Title

Hedge Funds Weigh In On Boston Scientific

Institutional investors and hedge funds have recently bought and sold shares of the business. Compass Capital Management Inc. grew its position in Boston Scientific by 21.7% during the first quarter. Compass Capital Management Inc. now owns 710,874 shares of the medical equipment provider’s stock valued at $44,607,000 after purchasing an additional 126,806 shares in the last quarter. Essential Partners LLC lifted its position in Boston Scientific by 2,209.1% in the 1st quarter. Essential Partners LLC now owns 1,016 shares of the medical equipment provider’s stock worth $64,000 after buying an additional 972 shares in the last quarter. Vestor Capital LLC purchased a new stake in Boston Scientific in the 1st quarter worth approximately $450,000. Edgestream Partners L.P. boosted its stake in shares of Boston Scientific by 340.7% during the 1st quarter. Edgestream Partners L.P. now owns 85,752 shares of the medical equipment provider’s stock valued at $5,381,000 after buying an additional 66,293 shares during the period. Finally, Kentucky Retirement Systems grew its holdings in shares of Boston Scientific by 18.9% during the 1st quarter. Kentucky Retirement Systems now owns 110,238 shares of the medical equipment provider’s stock valued at $6,917,000 after acquiring an additional 17,562 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Citigroup decreased their target price on Boston Scientific from $94.00 to $87.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $77.00 target price on shares of Boston Scientific in a report on Monday. Wells Fargo & Company decreased their price target on Boston Scientific from $94.00 to $75.00 and set an “overweight” rating for the company in a research report on Thursday, April 23rd. Mizuho dropped their price target on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. Finally, Royal Bank Of Canada cut their price objective on Boston Scientific from $105.00 to $100.00 and set an “outperform” rating on the stock in a report on Thursday, April 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $92.71.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.